veno

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows a Significant Reduction in Deep Vein Thrombosis and PulmonaryEmbolism Compared with Enoxaparin with Similarly Low BleedingRates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trialdata presented today at the XXI International Society on Thrombosisand Haemostasis (ISTH) Congress demonstrate that once-daily...

New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility

EXCLAIM is the First International Study to Show That ExtendedThromboprophylaxis Reduces VTE Risk in Acutely-ill Medical PatientsWith a Statistically Significant 44% PARIS, July 8, 2007 /PRNewswire-FirstCall/ --Sanofi-aventisannounced today the results of the EXCLAIM (EXtended CLinicalprophylaxis in Acutely Ill Medical patients) study, which showedthe benefit of extended prophylaxi...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase IIIclinical trial data presented today at the XXI InternationalSociety on Thrombosis and Haemostasis (ISTH) Congress demonstratethat once-daily rivaroxaban achieved superior efficacy in theprevention of venous thromboembolism (VTE) in patients undergoingknee replacement surgery in a head-to-head comparison withenoxaparin, the curren...

The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke

Risk of Having a Venous ThromboEmbolism (VTE) is Reduced by aSignificant 43% in Acute Ischemic Stroke Patients Treated WithClexane(R) / Lovenox(R) BRIDGEWATER, N.J., April 20, 2007 /PRNewswire-FirstCall/ --Sanofi-aventis announced the publication of the PREVAIL (Preventionof VTE after Acute Ischemic Stroke with LMWH Enoxaparin) trial inthe April 21st issue of The Lancet. The results of th...

Advanced Magnetics Announces Positive Results from Two Additional Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement Therapeutic

CAMBRIDGE, Mass., April 11, 2007 /PRNewswire-FirstCall/ --Advanced Magnetics today announced positive results from twoadditional Phase III clinical trials of ferumoxytol as anintravenous (IV) iron replacement therapeutic that are beingpresented today at approximately 6:00 pm EDT as posters at theNational Kidney Foundation's Spring Clinical Meeting in Orlando,Florida. These posters are av...

Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery

Data to be Presented at the XXI Congress of the InternationalSociety on Thrombosis and Haemostasis SOUTH SAN FRANCISCO, Calif., April 04, 2007 /PRNewswire/ --Portola Pharmaceuticals, Inc. today announced that it has receivedpositive results from EXPERT, a Phase II study of its oral FactorXa inhibitor, PRT054021, for the prevention of venousthromboembolism (VTE) following total knee replac...

Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in Their Phase 2 Clinical Trial

Iontophoretic Drug Delivery System, dermal patch and a directcurrent power source with lidocaine and epinephrine (IDDS) SEATTLE, March 20, 2007 /PRNewswire/ -- Dharma Therapeutics,Inc., ("Dharma") Seattle, WA, a transdermal drug delivery companyand wholly owned subsidiary of Transcutaneous Technologies, Inc.("TTI"), Tokyo, Japan announced that its active transdermaldelivery te...